New chairman, and docks walk ‘on’

Tim Bond, below, was elected chairman of Prospect at the 2021 AGM. He replaces Malcolm Gamlin, who retired after 13 years in the role. Malcolm was thanked for his hard work. Mick Broggio resigned as secretary so we are looking for a new one. Other committee members were re-elected.
The annual docks walk is on July 2. Meet at Cottage pub 10am. Ring Ken Head on 0117 929 3156 to confirm. And Penny Brohn has invited us on Tuesday July 27 – 12.30 lunch to 4pm. Register by text (preferred) or ring Tim Bond on 07824 556 786. The October 8 walk at Lansdown might be ‘on’ too. Zoom ‘coffee mornings’ are on the first Thursday of the month (10-noon). Information by email beforehand. New patients and current members are all welcome. Newbies can contact us via Contact us (above) or our Tackle helpline (0800 035 5302).

Enzalutamide (Xtandi) approved

Important news from NICE for the 4,100 men each year who are unsuitable for the standard treatment of docetaxel chemotherapy and who have, until now, had limited treatment options (June ’21) .  See more here:

Help with hearing problems

For anyone with hearing problems, this equipment is useful to amplify sound via a computer. It plugs via the USB cable and makes it easier to hear folk say on Zoom calls: Sennheiser EPOS SP 20 speakerphone. See
www.eposaudiocom/connect

Advanced US PCa tool approved

The US Food and Drug Administration has approved a new imaging agent to detect PCa after it has spread, the makers say. But it will not replace the PSA test (Jun ’21). See more here

New vaccine ‘could prevent PCa’

See here

Dogs sniff out worst cancers

Dogs can detect the most aggressive forms of PCa and could help develop a “robotic nose” to find the disease, a study says  (Feb ’21). More here. And another study suggests daily coffee drinking lowers PCa risk, (Feb ’21). More here

Take part in surveys

Prostate Cancer Research ask for your participation (from home) in surveys. People affected by PCa are instrumental in shaping what they do, so they’ve launched two patient-centred projects. They’re also running a special  survey with Ipsen UK&I to understand topics that patients find most tricky to talk about. More here

Drugs to fight cancer resistance

The world’s first drugs designed to stop cancer cells becoming resistant to treatment could be available within a decade, scientists have said (Jan ’21). More here

Urine test detects PCa

A new technique detects PCa with almost 100% accuracy within 20 minutes using only a urine sample (Jan ’21). More here

Bone scan breakthrough

A new bone scan technique can identify men with advanced prostate cancer who’ll benefit from radiotherapy. This ground-breaking achievement could help extend the lives of 25-30% of such patients (Jan ’21). See more here

Good news re Olaparib

Olaparib has given new hope to men with incurable PCa, says the Daily Mail in this article.

Big change in PCa diagnosis

The biggest diagnostic development in PCa diagnosis for 50 years – that came about when NICE advised that all men at risk of PCa should have an MRI before a biopsy. The change has had a worldwide effect. See more here

Cancer blood test trialled

A new blood test which might be able to detect 50 cancers is being trialled by the NHS. More here. And two professors have made a discovery that could turn cancer into a treatable disease (Sept ’20). See more here. And minscule robots can seek out cancer.cells and destroy them More here

Check your risk in 30 seconds!

An online 30-second risk checker has been launched which men are encouraged to take –  see here And a Prostate Cancer Research team are using machine learning to develop a new way to classify PCa and separate the “tigers” from the “pussycats” (Sept ’20). More here And a US study demonstrated the highest accuracy to date in recognising and characterising PCa using artificial intelligence (July ’20). More here Also a new blood test for PCa is producing 99% accuracy – the best yet. More here And a new 15-minute ‘game-changing’ test is announced here

Men set to lose out over abiraterone

Prostate Cancer UK are concerned that NICE is once again on the brink of rejecting abiraterone as a first-line treatment for men with high-risk advanced PCa. See more here  Earlier NICE had agreed to an appeal by Prostate Cancer UK to reverse its decision to restrict abiraterone for advanced PCa (Jul ’20). See more here. UK deaths from PCa exceeded 12,000 in 2019 for the first time and it overtook breast cancer as the most common cancer (June ’20). See more here. And a new type of immune cell which kills most cancers has been discovered. More info here  Screening: An expert explained why finding a suitable method is vital but is difficult. More here

Hormone treatment and Covid-19

Hormone treatment might offer some protection from Covid-19, it’s reported. See more here But it can make PCa worse, this study finds.  An online survey aiming to shed more light on the experience of PCa patients on this therapy (aged 35 to 80) is being conducted via this link And a London college has developed an online intervention to support men with PCa who have ongoing fatigue, and it is recruiting patients to take part. Information here. And an oil-based oral formulation has been found that not only enables a smaller dose of abiraterone to be effective but also has the potential to dramatically reduce possible side effects (Jun ’20). See more here

Chemo swapped for precision drugs

Advanced PCa patients can take enzalutamide or abiraterone at home instead of going into hospital for chemotherapy, NHS England says. It will relieve pressure on the NHS. The drugs are smarter, kinder treatments and could extend the lives of many more men, it’s said (May ’20). See more here: And a new treatment is being tested that could extend the lives of men with advanced prostate cancer, by killing cancer in the prostate despite the disease having spread. The nationwide Atlanta trial, at Imperial College London, was recruiting 918 newly-diagnosed men. Read more here.  And positive results have been reported from a trial that tested the PARP-inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant PCa who have alterations in certain DNA damage repair genes. Roughly 20-30% of these patients harbour these gene mutations in their tumours and thus may benefit from olaparib.

Patient guide ‘good source of info’

Prostate Cancer Foundation’s 2019 Patient Guide is said to be one of the best sources of information from diagnosis to survival of PCa. Download it for free here.  Our New Research page is updated regularly.

Drugs approved and a PCa ‘killer’

The NHS confirmed that the chemotherapy drug docetaxel will be made available to PCa patients as soon as they are diagnosed instead waiting until other treatments stop working. See.  And NICE has approved a new drug, Darolutamide, as an option for treating hormone-relapsed PCa in men at high risk of developing metastatic disease. See more here Also scientists have found that a natural insecticide kills advanced PCa cells. See more here More news on the newsletter page.